Navigation Links
Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Date:9/20/2007

ch will be administered by intramuscular injection at two-week intervals, and follow-up will continue for one year. The primary endpoint is the prevention of major amputation or of death. Additional information on the trial is available at http://en.sanofi-aventis.com/index.asp.

About Critical Limb Ischemia

Critical limb ischemia is a severe and costly condition. In the twelve months following the first episode of critical limb ischemia, 55% of patients either require amputation or die. In the United States and Europe, there are more than 150,000 amputations each year due to critical limb ischemia, with a direct cost of nearly $6 billion and a total cost of more than $8 billion. No disease-modifying therapy for critical limb ischemia is currently available.

About Vical

Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. Additional information on Vical is available at http://www.vical.com.

This press release contains forward-loo
'/>"/>

SOURCE Vical Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Vaccine Can Prevent Cervical Cancer and Precancerous Lesions
2. Largest Cervical Cancer Vaccine Efficacy Trial Shows Cervarix Provides Excellent Protection Against Lesions Caused by Most Common Cancer-Causing Virus Types
3. Vical Licensee AnGes MG Announces Positive Results of Phase 3 Angiogenesis Trial in Japan
4. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
5. Cervarix, the GSK Cervical Cancer Candidate Vaccine, Provides Sustained Immune Response in 100 Percent of Women up to 55 Years of Age
6. Vicals Vaxfectin Adjuvant With Needle-free Delivery Enhances DNA Vaccine Performance; Yields Antibody Responses Comparable to Electroporation Without Tolerability Issues
7. New England Journal of Medicine Publishes New Data on Gardasil, Mercks Cervical Cancer Vaccine
8. Cervarix, GSK Cervical Cancer Candidate Vaccine, Demonstrates 100 Percent Protection Against Precancerous Lesions Caused By Cancer-Causing Human Papillomavirus Types 16 & 18 for More Than Five Years
9. Vicals Vaxfectin Adjuvant Achieves Dose-Sparing Effect With Seasonal Influenza Vaccine
10. Nventa Announces Presentation of Positive HspE7 Data from NCI-Sponsored Clinical Trial in Cervical Dysplasia
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... , Oct. 30, 2014   BioLife Solutions , ... manufacturer and marketer of proprietary clinical grade hypothermic ... precision thermal shipping products for cells and ... 2014 financial results will be released on Thursday, November ... conference call and live webcast at 1:30 p.m. PST ...
(Date:10/30/2014)... MADRID , October 30, 2014 ... build tolerance for cow milk   Cow milk protein allergy ... infants and early childhood. Until now, it has been ... Recently, it has been shown that it is possible ... in a significant number of children during the first ...
(Date:10/30/2014)... -- Electrodes are devices that convert ionic potential ... diagnose as well as treat several ailments and ... the detection of chemical reactions derived from electrical ... the patients. In addition, few electrodes such as ... perform minimally invasive surgical procedures. The electrodes for ...
Breaking Medicine Technology:BioLife Solutions to Report Financial Results for Third Quarter 2014 and Provide Business Update on November 6, 2014 2Experts Present Latest Research at Allergy Day 2Experts Present Latest Research at Allergy Day 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 2Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 3Electrodes for Medical Devices Market (Diagnostic Electrodes - ECG, EEG, EMG, ERG and Fetal Scalp Electrodes, Therapeutic Electrodes - TENS, Pacemakers, Defibrillators, Electrosurgical and Other Electrodes) - Global Industry Analysis, Size, Share, G 4
... April 28, 2011 ResMed Inc. (NYSE: RMD ... ended March 31, 2011.  Revenue for the quarter ended March ... 12% increase on a constant currency basis) over the quarter ... 2011, income from operations was $64.0 million and net income ...
... Financial Highlights ($ in millions, except ... , $109.5 , 28.8% increaseTotal Net Product Revenue , ... , 24.7% increaseAldurazyme BioMarin Net Product Revenue* , $18.7 ... increaseFirdapse Net Product Revenue , $3.1 , $0.1GAAP Net ...
Cached Medicine Technology:ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 2ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 3ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 4ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 5ResMed Inc. Announces Record Financial Results for the Quarter Ended and Nine Months Ended March 31, 2011 6BioMarin Announces First Quarter 2011 Financial Results 2BioMarin Announces First Quarter 2011 Financial Results 3BioMarin Announces First Quarter 2011 Financial Results 4BioMarin Announces First Quarter 2011 Financial Results 5BioMarin Announces First Quarter 2011 Financial Results 6BioMarin Announces First Quarter 2011 Financial Results 7BioMarin Announces First Quarter 2011 Financial Results 8BioMarin Announces First Quarter 2011 Financial Results 9BioMarin Announces First Quarter 2011 Financial Results 10BioMarin Announces First Quarter 2011 Financial Results 11
(Date:10/30/2014)... October 30, 2014 High efficacy ... concepts in the medical-grade skin care domain: Cosmederm, ... of uniquely potent topical dermatological products, today announces ... http://www.RefinitySkinScience.com ) with patented COSMEDERM®-7 anti-irritant technology. ... concentrations (50% and 70%) and a low pH ...
(Date:10/30/2014)... New Haven, CT (PRWEB) October 30, 2014 ... product categories are raising questions about the impact of ... as the marketing method most likely to influence a ... online research poll of 525 consumers conducted by radio ... in four product categories, isolating the results of respondents ...
(Date:10/30/2014)... 30, 2014 Home Care Assistance – ... of non-medical, in-home senior care, is weighing in on ... health. , The study, performed by the University of ... and 78 over a week-long period and observed how ... physical activity. By examining the structural soundness of the ...
(Date:10/30/2014)... October 30, 2014 USARAD ... Accredited teleradiology and specialty telemedicine solutions provider, including ... to its existing teleradiology services at Mission Bend ... and expert telemedicine services, to the state-of-the-art, 24/7, ... a result of this innovative partnership, there will ...
(Date:10/30/2014)... October 30, 2014 Victory Healthcare, ... its 2014 third quarter infection rates and patient ... infection rates of only two percent or less, ... scores exceeding 98 percent. , “We are delighted ... included rising satisfaction scores,” said Robert Helms, chairman ...
Breaking Medicine News(10 mins):Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 2Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 3Health News:Cosmederm Redefines Peel Science Standard with Launch of Refinity® Skin Health System 4Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 2Health News:CRN Research On Radio Messaging Effectiveness Now Available In Four Specific Product Categories 3Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 2Health News:Home Care Assistance – Halton/Peel Region, a Top Provider of In-Home Care, Responds to Study Linking Exercise to Healthier Senior Brains 3Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 2Health News:USARAD HOLDINGS INC, SECONDOPINIONS.COM® Pioneers Specialty On-Demand Telemedicine And Second Opinion Service At Houston-Based, Mission Bend Freestanding ER Chain 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3
... support efforts to reduce air pollution, especially diesel exhaust ... studies from Europe demonstrate the health damage done by ... engines. , An 11-year period of improving air quality ... air in Europe, produced measurable benefits in lung function ...
... healthy lifestyle drives new store openings, PITTSBURGH, Dec. ... new resolution or two. For GNC, it means more ... is expected to rise steadily,through 2012, according to the ... to once again expand its store base and overall,business: ...
... Ky., Dec. 5 Ventas, Inc. (NYSE:,VTR) ... the Executive,Compensation Committee of its Board of ... certain executive officers to encourage their,long-term retention ... to,Raymond J. Lewis, the Company,s Chief Investment ...
... Growing price competition from,low-cost manufacturers has been forcing ... profitable growth, which Kalorama Information predicts,will likely come ... pharmaceutical,medical foods, or biomedical device companies -- a ... Healthcare Opportunities for Food Ingredient,Manufacturers., Thousands of ...
... still debated, experts say , , WEDNESDAY, Dec. 5 (HealthDay News) ... Wednesday that the cancer drug Avastin should not be used ... close vote, 5-4, the advisers decided the drug,s ability to ... increased risk of blood clots and other cardiovascular troubles among ...
... A new white paper,published by The Endocrine ... major new initiatives to ensure effective,broad-based minority participation ... of recommendations to ensure that data from clinical,trials ... The white paper, developed by a special ...
Cached Medicine News:Health News:Cleaner Air Leads to Healthier Lungs 2Health News:Cleaner Air Leads to Healthier Lungs 3Health News:GNC Franchising Expected to Grow Through 2008 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 2Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 3Health News:Ventas Grants Stock Awards to Promote Long-Term Retention and Reward Performance 4Health News:Medical Industry Offers Food Ingredient Companies More Than One Billion Reasons to Think Healthy 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 2Health News:FDA Panel Says No to Avastin for Advanced Breast Cancer 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 2Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 3Health News:The Endocrine Society Publishes White Paper Calling for Greater Minority Participation in Clinical Research 4
12 mm diameter pigtail curved probes with eyes 4mm back of blunt ends. Stainless steel. Round knurled handle with polished finish. Overall length: 5.9 inches....
The VISULAS 532s combines ease of use, efficiency and safety to provide ophthalmologists with an overall system sharply focused on their requirements. ,The VISULAS 532s is a laser of many talent...
Two point fixation, tips separated by 13 mm. Each tip has 0.12 mm, 1 x 2 teeth. Wide serrated handle with thumb catch lock and dull finish....
... 100 Hue Test including MS-Excel scoring template on ... 100 Hue Test comes boxed in clear acrylic ... potential for test disruption by holding the ... from Richmond Products includes 93 color discs, four ...
Medicine Products: